Corporate cycling day raises funds for cancer sufferers
Important cancer research and therapy was the big winner at the annual Penny’s Hill Peloton corporate event on Saturday 20 January.
Around 40 of the 120 guests braved the 35 degree temperatures to cycle all the way – with some spectacular scenery to distract them from challenging hills along the route from central Adelaide to the Penny’s Hill winery in McLaren Vale.
Refreshments and a very impressive guest speaker, Australian Olympic cyclist Annette Edmondson, were waiting at the end of the two-and-a-half hour ride.
A highlight of the afternoon was the enviable ringside view of the Tour Down Under Pelton which passed by five times during the day.
The event, which was hosted by Peet Limited and Finlaysons Lawyers, included a charity auction with all proceeds going to the Ryan Hodges Breathe Easy Fund.
Ryan, who was diagnosed with highly advanced cancer at just 32, shared his personal story with the guests and spoke about the charity he has since established to support ground-breaking research into precision medicine and targeted drug therapy for advanced stage cancer sufferers.
Around 40 of the 120 guests braved the 35 degree temperatures to cycle all the way – with some spectacular scenery to distract them from challenging hills along the route from central Adelaide to the Penny’s Hill winery in McLaren Vale.
Refreshments and a very impressive guest speaker, Australian Olympic cyclist Annette Edmondson, were waiting at the end of the two-and-a-half hour ride.
A highlight of the afternoon was the enviable ringside view of the Tour Down Under Pelton which passed by five times during the day.
The event, which was hosted by Peet Limited and Finlaysons Lawyers, included a charity auction with all proceeds going to the Ryan Hodges Breathe Easy Fund.
Ryan, who was diagnosed with highly advanced cancer at just 32, shared his personal story with the guests and spoke about the charity he has since established to support ground-breaking research into precision medicine and targeted drug therapy for advanced stage cancer sufferers.